diabetestalk.net

Victoza Vs Januvia

Efficacy And Safety Of Liraglutide Versus Sitagliptin, Both In Combination With Metformin, In Chinese Patients With Type 2 Diabetes: A 26week, Openlabel, Randomized, Active Comparator Clinical Trial

Efficacy And Safety Of Liraglutide Versus Sitagliptin, Both In Combination With Metformin, In Chinese Patients With Type 2 Diabetes: A 26week, Openlabel, Randomized, Active Comparator Clinical Trial

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26week, openlabel, randomized, active comparator clinical trial 1Department of Endocrinology, Chinese PLA General Hospital, Beijing, China 2Department of Endocrinology, Second Hospital of Jilin University, Jilin, China 3Department of Endocrinology, Harrison International Peace Hospital, Hengshui, China 4Department of Endocrinology, Chongqing Three Gorges Central Hospital, Chongqing, China 5Department of Endocrinology, Cangzhou People's Hospital, Cangzhou, China 6Department of Endocrinology, PLA, Military General Hospital of Beijing, Beijing, China 7Department of Endocrinology, Central Hospital of Minhang District, Shanghai, China 8Department of Endocrinology, Fifth People's Hospital of Shanghai, Shanghai, China 9Department of Endocrinology, Shanghai First People's Hospital, Shanghai, China 10Department of Endocrinology, Third Hospital of Hebei Medical University, Shijiazhuang, China 11Novo Nordisk (China) Pharmaceuticals Co., Ltd, Beijing, China *Correspondence to: Yiming Mu, Department of Endocrinology, Chinese People's Liberation Army General Hospital, 28 Fu Xing Road, Beijing 100853, China. Received 2015 Dec 18; Revised 2016 Mar 30; Accepted 2016 Apr 4. Copyright 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons AttributionNonCommercialNoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made. This article has been cited by other articles in PMC. To compare the efficacy and safety of liraglutide versus s Continue reading >>

Adding Sitagliptin To Liraglutide Provided No Extra Benefit In Diabetes

Adding Sitagliptin To Liraglutide Provided No Extra Benefit In Diabetes

Adding Sitagliptin to Liraglutide Provided No Extra Benefit in Diabetes Adding Sitagliptin to Liraglutide Provided No Extra Benefit in Diabetes Adding Sitagliptin to Liraglutide Provided No Extra Benefit in Diabetes BOSTON The addition of the dipeptidyl-peptidase-4 (DPP-4) inhibitor sitagliptin provided no added benefit in patients with diabetes who were being treated with the glucagon-like peptide (GLP-1) receptor agonist liraglutide, according to data presented at the American Diabetes Association (ADA) 75th Scientific Sessions. Both GLP-1 receptor agonists and DPP-4 inhibitors are incretin-based drugs. That, in the end, should at least partly explain the mechanism of action by an increased stimulation of GLP-1 receptors, Michael A. Nauck, MD, of St. Josef Hospital in Bochum, Germany, said during his presentation. It is unknown, however, whether co-administration of agents from both classes leads to more glucose-lowering effects. Therefore, Nauck and colleagues sought to study this more formally and mechanistically. In their study, the researchers evaluated 16 patients with type 2 diabetes (5 women, 11 men) with a mean age of 55 years and BMI of 31.7. Mean duration of diabetes was 9.4 years, metformin dose was 2,044 mg daily and HbA1c was 7.5%. At the time, patients were treated with metformin and liraglutide 1.2 mg daily, and were then randomly assigned sitagliptin or placebo. Glucose excursions after a mixed meal served as the primary endpoint, with researchers also looking at insulin secretion, C-peptide, glucagon, GLP-1 and total and intact gastric inhibitory polypeptide (GIP). The researchers assessed patients after an overnight fast, in randomized order, with sitagliptin 100 mg p.o. or matched placebo given 60 minutes before consumption of a standard mixed meal Continue reading >>

Victoza Vs Januvia (sitagliptin): A Head-to-head Comparison

Victoza Vs Januvia (sitagliptin): A Head-to-head Comparison

NNI Media Center > GLP-1 Receptor Agonists > Victoza vs Januvia (sitagliptin): A Head-to-Head Comparison Please review the Important Safety Information below prior to watching this video: Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. Victoza is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Victoza and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Victoza. Victoza (liraglutide) injection 1.2 mg or 1.8 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Victoza is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise. Acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with Victoza postmarketing. It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using Victoza; consider other antidiabetic therapies for these patients. Victoza is not a substitute for insulin and should not be used in patients with type 1 diabetes mellitus or diabetic k Continue reading >>

Januvia And Victoza

Januvia And Victoza

I was just on victoza but when I went to 3rd shift and medical issues with kid who finally is on the mend now that they did surgery on her wrist, my sugars started going up and they decided to add januvia to the mix. I will take 1.2 mg victoza in morning at breakfast before i go to bed then with dinner 1 pill 100mg of januvia. If that dont help then prandid. If that dont work then Dr will send me to a endocrinologist. Have any of you been on januvia or even better both januvia and victoza? If so how did it work out. D.D. Family Getting much harder to control Just saying hi, just a question even though I have never beeon on either but I am insulin I stiil have to limit carbs. I wish you the best orals for me did nothing. Both the shift change and your daughter's medical issues could surely raise BG, In my mind, the Januvia and the GLP-1 kind of work the same ground...I may be wrong. I was just on victoza but when I went to 3rd shift and medical issues with kid who finally is on the mend now that they did surgery on her wrist, my sugars started going up and they decided to add januvia to the mix. I will take 1.2 mg victoza in morning at breakfast before i go to bed then with dinner 1 pill 100mg of januvia. If that dont help then prandid. If that dont work then Dr will send me to a endocrinologist. Have any of you been on januvia or even better both januvia and victoza? If so how did it work out. Sent from my SM-G950U using Diabetes Daily mobile app I was started on Januvia because I am allergic to Metformin. My bg went down but was still too high. After several weeks I went on Victoza .6 for awhile, and then alternated 1.2 and 1.8 every other day for a week and then 1.8 a day. I do mine at nignt. We considered adding another med if needed but my A1C last week was 6.4 whi Continue reading >>

Compared With Januvia® Or Byetta® | Victoza® (liraglutide) Injection 1.2 Mg Or 1.8 Mg

Compared With Januvia® Or Byetta® | Victoza® (liraglutide) Injection 1.2 Mg Or 1.8 Mg

What is the most important information I should know about Victoza®? Victoza® may cause serious side effects, including: Possible thyroid tumors, including cancer. Tell your health care provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rats and mice, Victoza® and medicines that work like Victoza® caused thyroid tumors, including thyroid cancer. It is not known if Victoza® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Who should not use Victoza®? Do not use Victoza® if: you or any of your family have ever had MTC or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). you are allergic to liraglutide or any of the ingredients in Victoza®. What should I tell my health care provider before using Victoza®? Before using Victoza®, tell your health care provider if you: have or have had problems with your pancreas, kidneys, or liver. have any other medical conditions or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food. are pregnant or breastfeeding or plan to become pregnant or breastfeed. Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal supplements, and other medicines to treat diabetes, including insulin or sulfonylureas. How should I use Victoza®? You may give an injection of Victoza® and insulin in the same body area (such as your stomach area), but not right next to each other. Do not share your Victoza® pen with other people, even if the needle has been changed. You may give oth Continue reading >>

Compare Januvia Vs Victoza - Iodine.com

Compare Januvia Vs Victoza - Iodine.com

Head-to-head comparisons of medication uses, side effects, ratings, and more. Januvia (sitagliptin) is a good add-on treatment if your blood sugars are not controlled and you don't want to use an injectable medicine. 3.2/ 5 average rating with 143 reviewsforJanuvia Victoza (liraglutide) is a medicine you inject once a day to control diabetes, but it can be expensive. 4.7/ 5 average rating with 22 reviewsforVictoza Januvia (sitagliptin) is not linked to worsening heart failure like other medicines in its class. Uses the hormones naturally produced by your body to affect how sugar is processed. It is less likely to cause weight gain and low blood sugar compared to other diabetes medicines. Lowers A1c (average blood sugar over time) up to 1.5%. Helps with weight loss and controls appetite. Only medicine in this class with proven heart health benefits. No limitation for people with kidney problems, but close monitoring is recommended. Medicine is ready to use, without need to mix. Lowers A1c (average blood sugar over time) by less than 1%. Some people might get frequent cold-like symptoms. Rare but serious side effects include pancreatitis and severe joint pain. Brand name medicine and can be expensive. Compared to other similar medicines, you have to inject this every day. Continue reading >>

Novo's Pioneering Diabetes Pill Beats Victoza, Januvia In Tests

Novo's Pioneering Diabetes Pill Beats Victoza, Januvia In Tests

Novo's pioneering diabetes pill beats Victoza, Januvia in tests COPENHAGEN (Reuters) - Novo Nordisks experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck & Cos Januvia and its own best-selling injectable treatment Victoza in tests. FILE PHOTO: Employees stand in the insulin production plant of Danish multinational pharmaceutical company Novo Nordisk in Chartres, north-central France, April 21, 2016. REUTERS/Guillaume Souvant/Pool/File Photo The positive results in the latest of a series of pivotal clinical trials boost analysts expectations that Novos oral semaglutide medicine could become a multibillion-dollar blockbuster. Novo shares jumped more than 4 percent in early trade on Thursday. The trial against Victoza, a once-daily injection, met the primary endpoint of similar blood sugar reduction but was also superior on weight loss, Novo said in a statement late on Wednesday. This data is important, as it positions oral-sema as at least as good as the market leading injectable GLP-1, said Deutsche Bank analysts. The once-daily pill belongs to a blockbuster class of treatments known as GLP-1s that stimulate insulin production, the first of which were derived from the venomous bite of North Americas Gila monster lizard. So far, all have been injections. FILE PHOTO: The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres, north-central France, April 21, 2016. REUTERS/Guillaume Souvant/Pool/File Photo Deutsche believes oral semaglutide could eventually sell more than $5 billion a year and allow Novo to grow sales in the high-margin GLP-1 diabetes segment for years to come, with the new product potentially priced closer to expensive injection Continue reading >>

Selected Important Safety Information

Selected Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. Victoza® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Victoza® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Victoza®. Victoza® (liraglutide) injection 1.2 mg or 1.8 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established CV disease. Victoza® is not a substitute for insulin and should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis. Concurrent use with prandial insulin has not been studied. WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the hum Continue reading >>

Victoza® Consistently Outperformed Januvia® And Demonstrated Unsurpassed A1c Reductions Vs Trulicity®1-3

Victoza® Consistently Outperformed Januvia® And Demonstrated Unsurpassed A1c Reductions Vs Trulicity®1-3

WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. Victoza® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Victoza® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Victoza®. Victoza® (liraglutide) injection 1.2 mg or 1.8 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established CV disease. Victoza® is not a substitute for insulin and should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis. Concurrent use with prandial insulin has not been studied. WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the hum Continue reading >>

Januvia Vs Victoza - Medhelp

Januvia Vs Victoza - Medhelp

Common Questions and Answers about Januvia vs victoza I have Type 2 Diabetes and was put on Victoza yesterday, my doctor wants me to take this for weight loss. I would just like to know if anyone has lost weight or has had any side effects while taking this medication. I was on Byetta but the nausea never stopped and I felt bad all of the time. I took my first dose this morning of Victoza and so far there has been no nausea--I just hope it lasts. Any comments on this medication would greatly be appreciated. Copyright 1994-2018 MedHelp. All rights reserved. MedHelp is a division of Vitals Consumer Services, LLC. The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. MedHelp is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions . If you think you may have a medical emergency, call your physician or 911 immediately. Continue reading >>

Novo Nordisk's Victoza Boosted By Januvia Switch Trial Data - Pharmaphorum

Novo Nordisk's Victoza Boosted By Januvia Switch Trial Data - Pharmaphorum

Switching from Merck & Cos Januvia (sitagliptin) to Novo Nordisks Victoza (liraglutide) produced superior blood sugar reductions than continuing with the same treatment, according to latest trial data from the Danish pharma company. Novo Nordisk also announced encouraging phase3 data from its investigational drug semaglutide, which like Victoza is a GLP-1 class drug, but can be administered by injection weekly, not daily. Victoza is a key sales growth driver for Novo Nordisk. In 2015, sales were around $2.75 billion, a reported increase of 34% compared with 2014. The 26-week LIRA-SWITCH trial in adults assessed efficacy and safety of Victoza 1.8mg as an add-on to metformin in 407 adults with type 2 diabetes who switched from the DPP-4 inhibitor Januvia 100mg and metformin. Of the 407 adults uncontrolled on Januvia at week 26, those who switched to Victoza achieved a superior reduction HbA1c compared with those who continued their Januvia treatment. Those on Victoza had reduced HbA1c by 1.14%, compared with those in a Januvia group, whose HbA1c fell by 0.54%. Those who switched to Victoza experienced significantly greater body weight reductions versus those who continued with sitagliptin. On Victoza, 50.6% achieved HbA1c below 7%, compared with 26.9% of those on Januvia. On Victoza, 29.5% achieved HbA1c of 6.5% or below, compared with 9.9% on Januvia. Adverse events were more common in the Victoza group compared with Januvia (68.8% vs 56.9%) but there were no reports of severe hypoglycaemia and no reports of confimed nocturnal hypoglycaemia. Meanwhile Novo said its semaglutide 0.5mg and 1mg achieved significantly greater HbA1c reductions compared with placebo in a trial involving 388 adults. In the SUSTAIN 1 trial 74% of those on the lower strength and 72% of those on t Continue reading >>

Liraglutide Versus Sitagliptin In People With Type 2 Diabetes

Liraglutide Versus Sitagliptin In People With Type 2 Diabetes

This study compared the effectiveness and safety of liraglutide (Victoza) andsitagliptin (Januvia) in people with type 2 diabetes (T2D) who were being treated with metformin (Glucophage). It was determined that liraglutide controls blood glucose levels better, and results in more weight loss than sitagliptin. However, liraglutide was found to have more side effects. Control of blood glucose levels is important to prevent the long-term complications of T2D. Lifestyle changes can control blood glucose levels at first. However, most people will eventually need medications. Metformin is the first drug given to most people with T2D. It increases insulin sensitivity in the liver, decreasing the amount of glucose that the liver makes. Eventually, many people with T2D will need more drugs to control blood glucose levels. Liraglutide is a glucagon-like peptide 1 receptor agonist (GLP1RA). Glucagon-like peptide 1 (GLP1) is made in the intestines and released after a meal. GLP-1 stimulates the release of insulin (the hormone that lowers blood glucose) and inhibits the release of glucagon (hormone that raises blood glucose). These hormonal changes control blood glucose levels. GLP1RAs are drugs that mimic the effects of GLP1. Sitagliptin is a dipeptidyl peptidase-4 (DPP4) inhibitor. DPP4 inhibitors prevent the breakdown of GLP1, thus controlling blood glucose levels. It is not clear whether liraglutide or sitagliptin is more effective when used in combination with metformin. 5 studies comparing liraglutide with sitagliptin in people with T2D who were also being treated with metformin were examined. 1440 adults with T2D participated in these studies. 829 received liraglutide plus metformin. 611 received sitagliptin plus metformin. The participants were treated for at least 16 weeks Continue reading >>

Is It Ok To Take Januvia And Victoza At The Same Time Everyday, Or Should They Be Separated?

Is It Ok To Take Januvia And Victoza At The Same Time Everyday, Or Should They Be Separated?

Home Q & A Questions Is it ok to take Januvia and... Is it ok to take Januvia and Victoza at the same time everyday, or should they be separated? I myself would not take both together. They work in the same way. And are both black boxed warning. I'm thinking that would increas the chance of bad side effects. And the cancers it may cause. No results found - however, this does not necessarily mean no interactions exist. ALWAYS consult with your doctor or pharmacist. Other drugs that your selected drugs interact with Januvia (sitagliptin) interacts with more than 200 other drugs. Victoza (liraglutide) interacts with more than 200 other drugs. Interactions between your selected drugs and food Liraglutide may affect the absorption of other medications that you take by mouth. In some cases, this may affect how well and/or how fast those medications work, or it may make no difference. Talk to a healthcare provider if you have any questions or concerns, and contact your doctor if your symptoms worsen or your condition changes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor. Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences. The recommended maximum number of medicines in the 'incretin-based therapies' category to be taken concurrently is usually one. Yo Continue reading >>

Novo Nordisk's Oral Semaglutide Impresses Analysts Against Victoza, Januvia

Novo Nordisk's Oral Semaglutide Impresses Analysts Against Victoza, Januvia

Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia The latest data on Novo's oral semaglutide will be "critical for commercial positioning," Evercore ISI analyst Umer Raffat wrote. (Novo Nordisk) Once it wins approval, Novo Nordisks highly anticipated oral diabetes drug semaglutide will go up against some stiff competition. But the drugmaker just showed that its up-and-comer can take the heat. Wednesday, the company touted positive top-line data from a pair of studiesone pitting semaglutide against Novos own weekly GLP-1 injectable, Victoza, and one facing it off against Merck DPP-4 giant Januviathat Evercore ISI analyst Umer Raffat called critical for commercial positioning. Against Victoza, semaglutide put up better than expected results on its way to demonstrating noninferiority, as Bernsteins Wimal Kapadia wrote in a note to clients. Those included reductions to HbA1ca key measure of blood glucose control of 1.3% and 1.2% at 26 and 52 weeks, respectively, versus Victozas 1.1% and 0.9%. And in the weight-loss department, semaglutide proved superior: Semaglutide patients lost 4.7 and 5.0 kg at the same 26- and 52-week markers, compared with Victozas 3.2 and 3.1 kg showings. Like this story? Subscribe to FiercePharma! Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go. Continue reading >>

Comparing Diabetes Drugs: Januvia Vs. Victoza

Comparing Diabetes Drugs: Januvia Vs. Victoza

blood sugar control and lost more weight than patients who took the widely prescribed oral drug Januvia, a study shows. The trial is the first to compare two classes of diabetes drugs that target insulin-regulating hormones in the gut known as incretins, researchers say. Incretin-based drugs are most often prescribed to patients who do not achieve target blood sugar levels with the drug metformin or other oral agents for diabetes. Introduced early this year, Victoza is one of two FDA-approved drugs that mimic the activity of the naturally occurring incretin hormone GLP-1. The other is the twice-daily injected drug Byetta. Januvia works by blocking DDP-4, a key enzyme that breaks down GLP-1. Both classes of drugs increase insulin secretion and decrease secretion of the hormone glucagon, which raises blood sugar. In the new study, published April 24 in TheLancet, 665 type 2 diabetes patients who failed to achieve target blood sugar levels with metformin alone were treated with either once-daily injections of Victoza, at doses of 1.2 milligrams or 1.8 milligrams, or 100 milligrams of Januvia, taken by mouth once a day. Over 26 weeks of treatment, patients on the highest dosage of the injected drug achieved the best blood sugar control and the most weight loss. A main focus of the study was how well the two drugs lowered A1c, which measures blood sugar control over time. Nearly twice as many patients taking Victoza reached a target A1c level of less than 7%, according to study researcher Richard Pratley, MD, of the University of Vermont College of Medicine. The study was funded by Victoza manufacturer Novo Nordisk, which also participated in the study design, data collection, and data analysis. Pratley also acknowledged receiving consulting fees from both Novo Nordisk and M Continue reading >>

More in diabetes